1109 related articles for article (PubMed ID: 26162944)
1. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Morimoto T; Crawford B; Wada K; Ueda S
J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Tereshchenko LG; Henrikson CA; Cigarroa J; Steinberg JS
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207998
[TBL] [Abstract][Full Text] [Related]
8. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
9. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
10. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
11. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS
J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603
[TBL] [Abstract][Full Text] [Related]
12. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Liu X; Huang M; Ye C; Zeng J; Zeng C; Ma J
Medicine (Baltimore); 2020 Jul; 99(27):e21025. PubMed ID: 32629725
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
14. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
19. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
[TBL] [Abstract][Full Text] [Related]
20. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
